Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102816 | 0.93 | AAK1 (0.41) | AAK1REN | |
| SCHEMBL862032 | 0.83 | REN (0.42) | AAK1REN | |
| SCHEMBL862279 | 0.83 | REN (0.53) | REN | |
| SCHEMBL14543098 | 0.80 | REN (0.41) | REN | |
| SCHEMBL9907044 | 0.80 | REN (0.44) | REN | |
| SCHEMBL13090561 | 0.80 | REN (0.44) | REN | |
| SCHEMBL13093673 | 0.78 | REN (0.41) | REN | |
| SCHEMBL6948770 | 0.77 | REN (0.36) | AAK1REN | |
| SCHEMBL9907055 | 0.76 | REN (0.35) | REN | |
| SCHEMBL9907042 | 0.76 | REN (0.35) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100274027-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100274027-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-10-28 | — | — | US | disclosed |
| US-7767831-B2 | Process for preparing renin inhibitors | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-7767831-B2 | Process for preparing renin inhibitors | NOVARTIS AG (CH) | 2010-08-03 | — | — | US | disclosed |
| US-20080207921-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207921-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| WO-2006131304-A2 | PROCESS FOR PREPARING RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274027-A1 | ORGANIC COMPOUNDS | REN, AGTR1, GRHPR | AAK1 2661/4885REN 1/4885 |
| US-20080207921-A1 | Organic Compounds | REN, AGTR1, AGT | AAK1 1425/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.